Fairfield’s Rx Bandz has signed a memorandum of understanding (MOU) with Zeyco to fill and distribute its MiniJect® epinephrine auto-injector across Mexico, Central, and South America. This partnership aims to improve access to affordable, life-saving treatment for individuals with severe allergies.
“Zeyco is a world-class provider with extensive experience in epinephrine. We are honored to collaborate with them to expand access to this critical medication,” said Jessica Walsh, CEO of Rx Bandz. “Our MiniJect is a compact, patient-centric auto-injector with an extended shelf life and reduced environmental impact, addressing key barriers to use.”
Zeyco’s Pharmaceutical Plant Director, Alejandro Zepeda Sahagun, emphasized the urgent need for emergency epinephrine auto-injectors in Latin America. “Currently, there are no publicly available options in Mexico and many neighboring countries. Making MiniJect accessible will help prevent life-threatening anaphylactic reactions.”
Addressing a Critical Gap in Allergy Care
Epinephrine auto-injectors are the standard treatment for severe allergic reactions, but access remains limited. In Mexico, nearly 60 percent of patients cannot obtain treatment, primarily due to cost and availability. In the U.S., 60 percent of prescribed patients do not carry their auto-injectors, often due to the bulky design and expense of traditional devices.
Rx Bandz’s patented MiniJect® auto-injector offers a smaller, more portable solution with a longer shelf life of over two years, reducing costs for patients. The device is designed to administer a precise intramuscular dose, ensuring faster and more effective treatment.
